112 related articles for article (PubMed ID: 24621163)
1. Risk of anti-EGFR monoclonal antibody-related skin rash: an up-to-date meta-analysis of 25 randomized controlled trials.
Qi WX; Sun YJ; Shen Z; Yao Y
J Chemother; 2014 Dec; 26(6):359-68. PubMed ID: 24621163
[TBL] [Abstract][Full Text] [Related]
2. Electrolyte disorders assessment in solid tumor patients treated with anti-EGFR monoclonal antibodies: a pooled analysis of 25 randomized clinical trials.
Wang Q; Qi Y; Zhang D; Gong C; Yao A; Xiao Y; Yang J; Zhou F; Zhou Y
Tumour Biol; 2015 May; 36(5):3471-82. PubMed ID: 25542231
[TBL] [Abstract][Full Text] [Related]
3. Risk of high-grade skin rash in cancer patients treated with cetuximab--an antibody against epidermal growth factor receptor: systemic review and meta-analysis.
Su X; Lacouture ME; Jia Y; Wu S
Oncology; 2009; 77(2):124-33. PubMed ID: 19622903
[TBL] [Abstract][Full Text] [Related]
4. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials.
Li X; Shan BE; Wang J; Xing LP; Guo XJ; Zhang YH; Shi PH; Wang ZY
PLoS One; 2013; 8(11):e81897. PubMed ID: 24312376
[TBL] [Abstract][Full Text] [Related]
5. Incidence, risk and prognostic role of anti-epidermal growth factor receptor-induced skin rash in biliary cancer: a meta-analysis.
Wei F; Shin D; Cai X
Int J Clin Oncol; 2018 Jun; 23(3):443-451. PubMed ID: 29289981
[TBL] [Abstract][Full Text] [Related]
6. Incidence and risk of rash to mTOR inhibitors in cancer patients--a meta-analysis of randomized controlled trials.
Shameem R; Lacouture M; Wu S
Acta Oncol; 2015 Jan; 54(1):124-32. PubMed ID: 24914484
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk of severe infections associated with anti-epidermal growth factor receptor monoclonal antibodies in cancer patients: a systematic review and meta-analysis.
Qi WX; Fu S; Zhang Q; Guo XM
BMC Med; 2014 Nov; 12():203. PubMed ID: 25369798
[TBL] [Abstract][Full Text] [Related]
8. Skin toxicity with anti-EGFR monoclonal antibody in cancer patients: a meta-analysis of 65 randomized controlled trials.
Li J; Yan H
Cancer Chemother Pharmacol; 2018 Oct; 82(4):571-583. PubMed ID: 30006755
[TBL] [Abstract][Full Text] [Related]
9. Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer.
Waris W; Naik S; Idrees I; Taha H; Camosino L; Mehrishi A; Saif MW
Cutan Ocul Toxicol; 2009; 28(1):41-4. PubMed ID: 19514925
[TBL] [Abstract][Full Text] [Related]
10. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
11. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study.
Gatzemeier U; von Pawel J; Vynnychenko I; Zatloukal P; de Marinis F; Eberhardt WE; Paz-Ares L; Schumacher KM; Goddemeier T; O'Byrne KJ; Pirker R
Lancet Oncol; 2011 Jan; 12(1):30-7. PubMed ID: 21169060
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy.
Tejwani A; Wu S; Jia Y; Agulnik M; Millender L; Lacouture ME
Cancer; 2009 Mar; 115(6):1286-99. PubMed ID: 19170238
[TBL] [Abstract][Full Text] [Related]
13. The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials.
Petrelli F; Borgonovo K; Barni S
Target Oncol; 2013 Sep; 8(3):173-181. PubMed ID: 23321777
[TBL] [Abstract][Full Text] [Related]
14. Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: a literature-based meta-analysis of 24 trials.
Petrelli F; Borgonovo K; Cabiddu M; Lonati V; Barni S
Lung Cancer; 2012 Oct; 78(1):8-15. PubMed ID: 22795701
[TBL] [Abstract][Full Text] [Related]
15. Risk of skin rash associated with erlotinib in cancer patients: a meta-analysis.
Jia Y; Lacouture ME; Su X; Wu S
J Support Oncol; 2009; 7(6):211-7. PubMed ID: 20380328
[TBL] [Abstract][Full Text] [Related]
16. The risk of rash associated with ipilimumab in patients with cancer: a systematic review of the literature and meta-analysis.
Minkis K; Garden BC; Wu S; Pulitzer MP; Lacouture ME
J Am Acad Dermatol; 2013 Sep; 69(3):e121-8. PubMed ID: 23357570
[TBL] [Abstract][Full Text] [Related]
17. Risk of a lamotrigine-related skin rash: current meta-analysis and postmarketing cohort analysis.
Wang XQ; Xiong J; Xu WH; Yu SY; Huang XS; Zhang JT; Tian CL; Huang DH; Jia WQ; Lang SY
Seizure; 2015 Feb; 25():52-61. PubMed ID: 25645637
[TBL] [Abstract][Full Text] [Related]
18. Association of epidermal growth factor receptor polymorphism, skin toxicity, and outcome in patients with squamous cell carcinoma of the head and neck receiving cetuximab-docetaxel treatment.
Klinghammer K; Knödler M; Schmittel A; Budach V; Keilholz U; Tinhofer I
Clin Cancer Res; 2010 Jan; 16(1):304-10. PubMed ID: 20028750
[TBL] [Abstract][Full Text] [Related]
19. Risk of severe rash in cancer patients treated with EGFR tyrosine kinase inhibitors: a systematic review and meta-analysis.
Zhang X; Ran YG; Wang KJ
Future Oncol; 2016 Dec; 12(23):2741-2753. PubMed ID: 27522860
[TBL] [Abstract][Full Text] [Related]
20. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
